Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
Approximately $114 million in preliminary fourth quarter SYFOVRE®revenue as strong launch continues Approximately $24 million in preliminary fourth quarter EMPAVELI®revenue […]